Eli Lilly (LLY) Delivers +14.1% Gain Over 30 Days on Strong Fundamentals
Key Takeaways
- Eli Lilly shares surged approximately 14.1% over the past 30 days, climbing from $1,064.15 on June 2 to $1,213.91 on July 2, 2026.
- The rally was fueled by a combination of robust quarterly earnings, raised full-year guidance, and accelerating demand for the company’s GLP-1 obesity and diabetes franchises.
- Positive clinical data for next-generation metabolic therapies and favorable regulatory developments further amplified investor optimism.
- Over the last quarter, LLY gained roughly 27.2%, reflecting sustained momentum in the pharmaceutical giant’s core therapeutic areas.
- Analysts have revised price targets higher, citing Lilly’s expanding pipeline and dominant position in the cardiometabolic market.
Eli Lilly (LLY) Company Snapshot and Market Position
Eli Lilly and Company is a global pharmaceutical leader headquartered in Indianapolis, Indiana. The company develops and commercializes medicines across several therapeutic areas, including diabetes, obesity, oncology, immunology, and neuroscience. Lilly’s portfolio features blockbuster GLP-1 receptor agonists such as Mounjaro for type 2 diabetes and Zepbound for chronic weight management, which have reshaped the obesity treatment landscape. The company also markets Verzenio for breast cancer, Taltz for psoriasis, and recently launched donanemab for early Alzheimer’s disease. With a deep pipeline of next-generation metabolic, gene therapy, and RNA-based candidates, Lilly is widely regarded as one of the most innovative large-cap pharmaceutical companies. Investors closely track the stock due to its exposure to high-growth therapeutic categories and its ability to deliver consistent revenue and earnings expansion.
LLY Stock Price Performance: Last 30 Days Compared to the Quarter
LLY shares delivered a powerful 14.1% return over the 30-day period ending July 2, 2026. The stock opened the period at $1,064.15 on June 2 and closed at $1,213.91 on July 2, adding approximately $149.76 per share. The move was punctuated by a sharp single-day advance on June 26, when the stock jumped from $1,127.69 to $1,208.12, reflecting a major catalyst that reset investor expectations. Over the broader quarter, the performance was even more striking. From the April 1 close of $954.52 to the July 2 close of $1,213.91, LLY gained 27.2%, underscoring a multi-month uptrend driven by fundamental strength and improving sentiment. The stock consistently traded above key moving averages, and volume patterns confirmed institutional accumulation during both the 30-day and quarterly windows.
What Drove the 30-Day Surge in LLY Shares
The 30-day surge in LLY shares was propelled by several reinforcing catalysts. First, the company reported first-quarter 2026 results that exceeded consensus estimates on both revenue and earnings, driven by surging sales of Mounjaro and Zepbound. Management raised full-year revenue and EPS guidance, citing stronger-than-expected demand and improving supply chain capacity. Second, Lilly presented positive Phase 3 data for an oral GLP-1 candidate, which demonstrated competitive efficacy and a favorable safety profile, positioning the company to capture a larger share of the oral obesity market. Third, the Centers for Medicare & Medicaid Services issued a final coverage determination expanding access to anti-obesity medications for Medicare beneficiaries, a policy shift that directly benefits Lilly’s Zepbound franchise. Additionally, several Wall Street analysts upgraded the stock and lifted price targets, citing the company’s durable competitive moat and pipeline optionality. The combination of earnings momentum, pipeline progress, and a favorable regulatory environment created a powerful tailwind that drove the stock sharply higher.
Drivers Behind LLY’s 27.2% Quarterly Advance
LLY’s 27.2% quarterly gain was built on a foundation of sustained execution and expanding market opportunities. Throughout the second quarter of 2026, the company benefited from a steady cadence of positive news flow. Manufacturing capacity expansions alleviated earlier supply constraints for incretin-based therapies, enabling broader patient access and accelerating prescription growth. Lilly also advanced its next-generation obesity pipeline, including triple-agonist and oral small-molecule programs, reinforcing its long-term growth narrative. The broader healthcare sector experienced a rotation as investors sought defensive growth amid macroeconomic uncertainty, and Lilly’s combination of high revenue visibility and pipeline optionality made it a preferred destination for capital. The quarterly performance was further supported by the company’s capital allocation strategy, which included a dividend increase and a share repurchase authorization, signaling management’s confidence in the business outlook.
Using AI Tools to Navigate Market Moves
In a market environment where rapid price moves can create both opportunity and risk, many traders are turning to AI-driven tools to help navigate volatility. I often review Tickeron’s Trending AI Robots page, which showcases a curated selection of top-performing AI trading bots from a universe of hundreds that trade thousands of tickers. These bots employ diverse strategies, timeframes, and performance metrics, allowing users to identify approaches that align with their own trading objectives. The curated list highlights bots that have demonstrated consistent results and relevance in current market conditions, making it a practical starting point for those interested in algorithmic trading. I find it useful to check the Trending AI Robots section periodically to see which strategies are gaining traction right now.
Key Factors to Watch for LLY Going Forward
Looking ahead, several factors will influence LLY’s trajectory. The company’s second-quarter 2026 earnings report, expected in early August, will be a critical checkpoint for sales trends, margin performance, and updated guidance. Investors will also monitor prescription data for Mounjaro and Zepbound, as well as any commentary on competitive dynamics from emerging oral GLP-1 entrants. Regulatory decisions on label expansions and international market access for donanemab could serve as additional catalysts. Macroeconomic variables, including interest rate policy and healthcare spending trends, may impact valuation multiples across the pharmaceutical sector. Finally, pipeline milestones—particularly Phase 2 and Phase 3 readouts for next-generation metabolic candidates—will be closely watched as indicators of Lilly’s ability to sustain its growth trajectory beyond the current product cycle.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
LLY sees MACD Histogram crosses below signal line
LLY saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 05, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 45 instances where the indicator turned negative. In 33 of the 45 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 73%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LLY as a result. In 53 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 64%.
LLY moved below its 50-day moving average on September 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for LLY crossed bearishly below the 50-day moving average on September 04, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 69%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LLY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.
The Aroon Indicator for LLY entered a downward trend on September 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where LLY's RSI Oscillator exited the oversold zone, 18 of 23 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +0.24% 3-day Advance, the price is estimated to grow further. Considering data from situations where LLY advanced for three days, in 263 of 376 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 12 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 65, placing this stock better than average.
The Tickeron SMR rating for this company is 14 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. LLY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 51 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (31.153) is normal, around the industry mean (19.199). P/E Ratio (39.771) is within average values for comparable stocks, (34.793). Projected Growth (PEG Ratio) (1.170) is also within normal values, averaging (5.738). LLY has a moderately low Dividend Yield (0.006) as compared to the industry average of (0.025). LLY's P/S Ratio (12.804) is very high in comparison to the industry average of (4.033).
The Tickeron PE Growth Rating for this company is 58 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of pharmaceutical products
Industry PharmaceuticalsMajor
Advertisement